Hansson M, Söderström T
Department of Clinical Immunology and Transfusion Medicine, Karolinska Hospital, Stockholm, Sweden.
Med Oncol Tumor Pharmacother. 1993;10(1-2):5-12. doi: 10.1007/BF02987762.
Hematopoiesis is a dynamic process, which generate in the range of 10(9) cells/kg each day of erythroid and myeloid cells respectively. In vitro assays that were developed 20 years ago, have been used to define factors that can stimulate growth and differentiation of bone marrow (BM) derived progenitor cells. These growth factors for hematopoiesis were termed Colony Stimulating Factors (CSFs) since the assay system was to induce colonies. With the application of molecular biologic approaches, the genes encoding for these CSFs have been localized and cloned. Production of CSFs and other soluble signal substances (cytokines) as pure proteins have led to important insights into how hematopoiesis is regulated by a complex network made up by interactions between cells and cytokines. The availability of CSFs in clinically useful amounts has also led to clinical trials with new strategies for treating hematopoietic dysfunctions, congenital or acquired. Because others have recently reviewed clinical applications or basic science studies on the colony stimulating factors, we will summarize the two with focus on common features between the different CSFs.
造血是一个动态过程，每天分别产生10⁹个红细胞和髓细胞/千克。20年前开发的体外试验已被用于确定能够刺激骨髓来源祖细胞生长和分化的因子。由于该试验系统旨在诱导集落形成，这些造血生长因子被称为集落刺激因子（CSF）。随着分子生物学方法的应用，编码这些CSF的基因已被定位和克隆。以纯蛋白形式生产CSF和其他可溶性信号物质（细胞因子），使人们对由细胞与细胞因子之间相互作用构成的复杂网络如何调节造血有了重要认识。临床上可用量的CSF的出现，也引发了治疗先天性或后天性造血功能障碍新策略的临床试验。由于最近其他人已经综述了关于集落刺激因子的临床应用或基础科学研究，我们将对二者进行总结，重点关注不同CSF之间的共同特征。
